News | June 11, 2024
Abbott wins CE mark for dual-chamber leadless pacemaker
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated
